12 hours Ago By Defense World Staff
Waterloo Capital L.P. reduced its stake in Johnson & Johnson ( NYSE:JNJ – Free Report ) by 49.
5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,188 shares of the company’s stock after selling 4,104 shares during the period. Waterloo Capital L.
P.’s holdings in Johnson & Johnson were worth $612,000 as of its most recent SEC filing. A number of other institutional investors have also recently modified their holdings of the stock.
Shariaportfolio Inc. grew its stake in shares of Johnson & Johnson by 12.7% in the second quarter.
Shariaportfolio Inc. now owns 16,513 shares of the company’s stock worth $2,414,000 after acquiring an additional 1,858 shares during the last quarter. Blair William & Co.
IL grew its stake in shares of Johnson & Johnson by 12.3% in the second quarter. Blair William & Co.
IL now owns 1,045,546 shares of the company’s stock worth $152,817,000 after acquiring an additional 114,780 shares during the last quarter. O Brien Greene & Co. Inc boosted its position in shares of Johnson & Johnson by 9.
1% during the second quarter. O Brien Greene & Co. Inc now owns 9,567 shares of the company’s stock valued at $1,398,000 after buying an additional 797 shares during the last quarter.
Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Johnson & Johnson by 6.6% during the second quarter.
Meiji Yasuda Asset Management Co Ltd. now owns 135,526 shares of the company’s stock valued at $19,808,000 after buying an additional 8,408 shares during the last quarter. Finally, Argent Trust Co boosted its position in shares of Johnson & Johnson by 0.
5% during the second quarter. Argent Trust Co now owns 189,595 shares of the company’s stock valued at $27,711,000 after buying an additional 963 shares during the last quarter. 69.
55% of the stock is owned by hedge funds and other institutional investors. Analysts Set New Price Targets Several equities research analysts recently commented on JNJ shares. TD Cowen dropped their price objective on Johnson & Johnson from $195.
00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Morgan Stanley increased their price objective on Johnson & Johnson from $167.
00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.
00 price objective on shares of Johnson & Johnson in a research report on Monday. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.
00 in a research report on Thursday, July 18th. Finally, The Goldman Sachs Group lowered their target price on Johnson & Johnson from $160.00 to $155.
00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.
21. Insider Transactions at Johnson & Johnson In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th.
The stock was sold at an average price of $165.06, for a total value of $930,113.10.
Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link .
Corporate insiders own 0.16% of the company’s stock. Johnson & Johnson Stock Down 0.
5 % NYSE JNJ opened at $166.17 on Thursday. The stock’s 50-day moving average price is $160.
71 and its 200-day moving average price is $154.09. The company has a quick ratio of 0.
85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.
Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85.
The company has a market capitalization of $399.92 billion, a P/E ratio of 10.36, a price-to-earnings-growth ratio of 2.
71 and a beta of 0.53. Johnson & Johnson ( NYSE:JNJ – Get Free Report ) last posted its quarterly earnings data on Wednesday, July 17th.
The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.
11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.
34%. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.
33 billion. During the same quarter last year, the company earned $2.80 earnings per share.
The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 10.
02 earnings per share for the current year. Johnson & Johnson Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a $1.
24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 2.
98%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.
92%. About Johnson & Johnson ( Free Report ) Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Stories Five stocks we like better than Johnson & Johnson How the NYSE and NASDAQ are Different, Why That Matters to Investors How Much Can You Make in Stocks in One Month? What is the FTSE 100 index? This Is the Top Large-Cap Stock Insiders Are Buying What is the S&P/TSX Index? Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter ..
